This review summarizes recent reports on nonallergen-specific therapies for food allergy. These therapies are especially appealing for food allergy because unlike allergen-specific immunotherapy, they would allow the treatment of multiple food allergies in a single patient with one therapy.
INTRODUCTION
With an increasing amount of research being dedicated to the field of food allergy, the onceunattainable idea of an active, readily available, immune-modulating therapy for patients with food allergy may soon be a reality. The majority of published reports and ongoing studies in this field employ allergen-specific immunotherapy to achieve either a state of desensitization, or hopefully, a state of tolerance [1] [2] [3] [4] [5] [6] . Although these methods, reviewed in depth by other articles in this issue, show great promise for practicing clinicians and their patients, they may have one inherent drawback in the real world, which is that many foodallergic patients are polysensitized and allergic to multiple foods. For example, if these immunotherapy protocols are employed in everyday practice, what would one do for their patient who is allergic to milk, egg, peanut, and shellfish? Will these patients require a physician-prepared cocktail of allergens for desensitization? Or will they have to be desensitized to one food at a time? One option that circumvents this inevitability is the use of allergen nonspecific therapies. The goal of these therapies is to induce a state of tolerance by altering the global host immune response, rather than that specified to a single allergen. Although this may be a holy grail in the field of allergy, there are some reports to suggest that we are getting closer, as several nonspecific therapies are currently being investigated.
CHINESE HERBAL THERAPY
Although traditional Chinese medicine, which encompasses various practices including herbal therapy, acupuncture, dietary therapy, and mindbody therapy, has been in use for centuries in Asian countries, it is still considered alternative medicine in the Western societies. This stigma is beginning to change, however, as researchers are putting many of these therapies through stringent, scientific trials in order to prove or disprove their efficacy [7] . In the field of allergic diseases, the majority of the randomized controlled clinical trials studying traditional Chinese medicine involve herbal therapies for atopic dermatitis or asthma [8] [9] [10] [11] [12] [13] [14] [15] [16] . There are fewer trials studying traditional Chinese medicine in food allergy, although this trend is changing with some promising data in both animal models and in human clinical trials being reported in the last few years.
Murine model in food allergy
In 2001, Li et al. [17] first reported the effects of a formula containing 11 different herbs, termed the Food Allergy Herbal Formula (FAHF)-1, in a mouse model of peanut allergy. The formula was initially based on the herbal therapy, Wu Mei Wan, which has been used to treat gastroenteritis and asthma [18] . In that report, C3H/HeJ mice sensitized to peanut were treated with either FAHF-1 or water twice daily for 7 weeks after sensitization. Upon posttherapy peanut challenge, mice treated with FAHF-1 had no symptoms of anaphylaxis, whereas the sham-treated mice had significantly elevated anaphylaxis scores and had significant decreases in body temperature. This clinical effect was associated with significantly lower plasma histamine levels, lower numbers of degranulated tissue mast cells, and lower levels of peanut-specific serum IgE.
In an attempt to simplify the formula and increase its safety, the researchers later modified FAHF-1 by removing two of the herbs, which were potentially toxic if processed improperly. The resultant nine-herb formulation was termed FAHF-2, and its efficacy and safety were studied in the same murine model of peanut anaphylaxis [19] . In that report, FAHF-2-treated mice, unlike sham-treated mice, had no signs of peanut-induced anaphylaxis upon challenge 1-week posttherapy. The effect did not appear to be transient, as FAHF-2-treated mice continued to have completely abrogated responses to peanut challenges at 3 and 5 weeks posttherapy, whereas sham-treated mice continued to exhibit anaphylaxis. This clinical effect was again associated with decreased plasma histamine levels, decreased vascular leakage, decreased peanut-specific IgE levels, and increased peanut-specific IgG2a level.
In a follow-up study of the duration of action, Srivastava et al. [20] showed that at 26 weeks posttherapy, all of the FAHF-2-treated mice remained completely protected from anaphylaxis upon peanut challenge, whereas all of the sham-treated mice exhibited signs of anaphylaxis (including one death). The effect was persistent at 36 weeks posttherapy, although it was not as effective at this point, as three of the eight mice treated with FAHF-2 exhibited moderate allergic reactions.
Mechanism of action
The therapeutic effect of FAHF-2 appears to be at least partially dependent upon a shift in immune response from a T helper (Th)-2 response to a Th1 response. All of the murine studies [19] [20] [21] have shown decreases in IL-4, IL-5, and IL-13 levels and increases in IFN-g from splenocytes or mesenteric lymph node cells of FAHF-2-treated mice. The elevated levels of IFN-g, later discovered to be the product of CD8 þ T cells, appeared to be one of the keys to the formula's effect [21] . In fact, depletion of IFN-g or CD8 þ T cells blocked the suppression of IgE and Th2 cytokine responses generated by FAHF-2 [20] . Interestingly, this immune-modulatory effect did not correlate completely with the clinical effect. Although the anti-IFN-g antibody could block the Th2 to Th1 shift caused by FAHF-2 throughout treatment, it did not block the clinical effects of FAHF-2 immediately (1 week) posttherapy, rather abrogation of the clinical effects of FAHF-2 by anti-IFN-g were not seen until the second peanut challenge 4 weeks later [20] . The researchers hypothesized that FAHF-2 could, therefore, be working on mast cells and basophils through both IFN-g-dependent and IFNg-independent mechanisms. They went on to show that FAHF-2-treated mice had lower numbers of peripheral blood basophils and peritoneal mast cells
KEY POINTS
The Food Allergy Herbal Formula 2 is a Chinese herbal therapy that has been shown to abrogate anaphylaxis in a mouse model of peanut anaphylaxis, and is now being investigated in a phase II efficacy trial in humans.
Early studies with anti-IgE therapy appeared to confer increased tolerance in only a subset of peanut-allergic individuals. More recent studies are exploring its use as an adjunct to food-allergen immunotherapy.
Probiotics have been studied extensively in atopic disease, and although they may improve atopic dermatitis in some patients, they do not currently have a role in the prevention or treatment of food allergy.
Lactic acid bacteria engineered to express food allergens and/or cytokines that dampen or shift the allergic immune response have been shown to have potential in the treatment of food allergy in a mouse model.
Data on the treatment of atopic disease with helminth therapy, namely Trichuris suis ova, have been controversial; however, reports from its use in inflammatory bowel disease and in murine models of food anaphylaxis provide hope for its success in food allergy.
than sham-treated controls. In addition, in a mast cell line, FAHF-2 inhibited IgE-stimulated mast cell proliferation and IgE-mediated upregulation of the high affinity IgE receptor (FceRIa) [22] . Therefore, it appeared that FAHF-2 had more than a single mechanism of action, which may reflect the fact that it is a combination of multiple herbs that may have different effects on the immune system.
When examining each herb individually, Kattan et al. [23] found that no single herb in the FAHF-2 formula could reproduce the clinical effect of the entire formula. Even when attempting to create a simplified version of the formula using what appeared to be the three most potent ingredients, the authors found that the simplified formula was only partially effective. Therefore, the combination of the nine herbs in FAHF-2 acting in concert is required to achieve the full effect.
Human studies
Based on the success of FAHF-2 in the murine model, studies [24
& ] of the efficacy and safety of FAHF-2 have now been initiated in humans. The initial phase I trial of FAHF-2 examined the safety and dose tolerability of FAHF-2 using a randomized, double-blind, placebo-controlled, dose-escalation trial design [24 & ]. Three doses of FAHF-2 were used: 2.2 g (four tablets), 3.3 g (six tablets), or 6.6 g (12 tablets), which were taken three times daily for 7 days. Overall, the treatment was very well tolerated. Adverse events included one patient in the placebo group reporting vomiting and one patient in the active group reporting loose stools. In addition, one patient in the active arm did withdraw due to a rash, but after evaluation, this was deemed to be a flare of his underlying atopic dermatitis and unlikely related to the medication. Initial immunologic analysis after 7 days of treatment showed no effect on allergen-specific IgE levels or skin prick test results, but those in the active arm did have significantly lower levels of IL-5 after treatment, which was not seen in the placebo group.
More recently, results of the extended, openlabel phase I trial of FAHF-2 have been reported [25 & ]. In this study, participants received 3.3 g (six tablets) of FAHF-2 three times daily for 6 months in order to look at long-term safety. Eighteen individuals were enrolled and 14 completed the study, with the reasons for withdrawal being pregnancy (one), difficulty with compliance due to time commitment and number of tablets to swallow (two), and abdominal pain (one). Among the 14 individuals who completed the study, there was only one adverse event noted during the 6 months of treatment; this patient had eosinophilic esophagitis thought to be in remission prior to study entry, but experienced a recurrence of symptoms (abdominal pain, dysphagia, and food impaction) during the treatment period. After initiating treatment for her eosinophilic esophagitis, this patient was able to complete the 6 months of FAHF-2. In regard to laboratory findings, there were no changes seen in hematology or chemistry laboratory values, pulmonary function tests, or electrocardiographic findings at baseline, 2, 4 or 6 months of treatment. In this extended phase I trial, the authors also showed some mechanistic data, with evidence of decreased percentages of CD63 þ basophils in peripheral blood upon antigen stimulation after 6 months of treatment.
Future endeavors and obstacles
Currently, a multicenter, double-blind, placebocontrolled phase II trial is ongoing (Clinicaltrials. gov identifier: NCT00602160). In this study, participants are randomized to receive FAHF-2 or placebo tablets at a dose of 10 tablets three times daily. This large tablet load is a barrier to adherence; therefore, newer extraction techniques are being explored. One such technique, butanol extraction, is able to decrease the effective volume of the compound by approximately five fold. The clinical efficacy of this product has been demonstrated in the mouse model [26] . Additional studies are planned to determine the safety of this product in humans.
ANTI-IGE THERAPY
The rationale behind the use of anti-IgE therapy for food allergy is no different than for its use in other atopic conditions. By decreasing free serum IgE levels and downregulating the expression of the high-affinity IgE receptor, anti-IgE therapy should theoretically decrease IgE-dependent mast cell and basophil responses to ingested allergen as it does to inhaled allergens.
Initial study
Data for the use of anti-IgE therapy in food allergy were first reported in 2003 [27] . In the initial trial, 84 peanut-allergic individuals, 12-64 years of age, were randomized to receive one of three doses (150, 300, and 450 mg) of a humanized, monoclonal anti-IgE antibody known as TNX-901 (also known as Hu-901) or placebo. All individuals had an entry doubleblinded peanut challenge and a posttreatment open peanut challenge 2-4 weeks after completion of therapy. Treatment with TNX-901 increased the eliciting threshold dose of peanut at the posttreatment challenge in a dose-dependent manner; however, only the highest dose (450 mg) produced a statistically significant difference over placebo. Furthermore, the efficacy of this treatment was not uniform for individuals; although 25% of patients were able to tolerate over 20 peanuts following therapy, another 25% failed to develop any improvement in tolerance.
Omalizumab and food allergy
The promising results of the initial anti-IgE therapy in food allergy led to a double-blind trial of the currently commercially available anti-IgE antibody, omalizumab (Xolair; Genentech, South San Francisco, CA), in peanut allergy [28 && ]. In this trial, peanut allergic patients (6-75 years old) were randomized to receive either omalizumab or placebo in a 2 : 1 ratio. Unfortunately, this study was cut short due to the severity of two anaphylactic reactions during the baseline, qualifying peanut challenges (prior to the administration of any study drug). Only 14 individuals completed the trial up to that point (nine in the active arm and five in the placebo arm). Given that the study was initially powered to enroll 150 individuals, it is not surprising that the data did not reach statistical significance. However, as with the initial trial of anti-IgE therapy, omalizumab showed promising results suggesting that anti-IgE can increase the threshold dose required to elicit a reaction. When comparing the baseline tolerable peanut dose to the post-24 week treatment tolerable dose, there was a trend of increased peanut tolerability in the omalizumab-treated individuals compared with the placebo-treated individuals (P ¼ 0.054). In addition, 44% of the omalizumab-treated individuals were able to tolerate the goal dose of 1 g of peanut protein after 24 weeks of treatment compared with only one individual in the placebo-treated arm. Thus, it is possible that anti-IgE therapy could decrease the chances of an allergic reaction due to accidental ingestion, but it is unclear whether it could lead to tolerance.
Future directions
Just as omalizumab has been used as an adjunctive therapy to increase efficacy and decrease adverse reactions with immunotherapy for respiratory allergy [29] , there may be a role for its use as an adjunct to immunotherapy for food allergy. Although there are several promising reports on oral immunotherapy (OIT) for food allergy, this treatment is not without risks. Difficulties with oral and gastrointestinal side effects, as well as systemic allergic reactions have been reported with OIT [30] . The addition of anti-IgE therapy to food immunotherapy may accelerate the desensitization process while minimizing adverse effects.
Preliminary results have now been published for one such study examining the use of omalizumab in a rush protocol of milk OIT [31 & ]. In this brief communication, the authors showed that treatment with omalizumab 7-11 weeks prior to initiating milk OIT allowed nine of the 11 enrolled individuals to tolerate the 1-day rush desensitization protocol going from 0.1 to 1000 mg of milk protein. This was a pilot study, lacking a placebo group and baseline double-blinded milk challenge; however, it points to the potential use of omalizumab with food OIT, and there are now ongoing trials currently assessing the use of anti-IgE with OIT to various foods (Clinicaltrials.gov identifiers: NCT01157117, NCT00932282, NCT01290913).
PROBIOTICS AND PREBIOTICS
Probiotics and prebiotics have been studied at length as a means of both prevention and treatment of atopic diseases. Most of the randomized, clinical trials using probiotics have examined their effects on atopic dermatitis [32] [33] [34] [35] [36] [37] [38] ; however, there are a few studies that have examined their effect on food allergy. Here, we review only those clinical trials that report data on food allergy outcomes since the publication of the most recent review on the topic in this journal [39] . When interpreting these studies, it is important to note that the study population, microorganisms used, doses, and durations of therapy can vary greatly.
Murine model
Schiavi et al. [40] examined a probiotic mixture of eight different bacterial strains (Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus casei, Lactobacillus plantarum, Bifidobacterium longum. Bifidobacterium infantis, Bifidobacterium breve, and Streptococcus salivarius) in a shrimp tropomyosinsensitized mouse model. The authors found that treatment with the probiotic mixture after sensitization could decrease anaphylaxis scores upon antigen challenge, with a concomitant decrease in fecal histamine levels as compared with sham-treated controls. This effect was associated with a decrease in tissue levels of Th2 cytokines and an increase in the tissue levels of regulatory cytokines.
Human studies
Human studies of probiotics for atopic diseases have not been very conclusive to date, and the most recent Cochrane review of probiotics for eczema concluded that there was evidence to suggest that probiotics were not effective in treating eczema [41] . As stated earlier, there are even fewer data on their use in food allergy. A recent randomized trial of Lactobacillus GG in an extensively hydrolyzed casein formula (EHCF) compared to EHCF alone demonstrated that infants on the supplemented formula developed tolerance to cow's milk at a faster rate [42] . In perhaps the best trial of probiotics in food allergy to date, Hol et al. [43] examined the use of probiotics (Lactobacillus casei and Bifidobacterium lactis, each at 10 7 colonyforming units/gram of formula) in children with diagnosed cow's milk allergy using a randomized, double-blind, placebo-controlled design. The authors showed that there was no difference in the development of tolerance to cow's milk after 6 or 12 months of treatment between the probiotic and placebo groups, based on double-blind, placebocontrolled oral food challenges. In addition, there was no difference in sensitization rates to milk, egg, or soy between the two groups. These findings on sensitization rates are similar to those reported in double-blind, placebo controlled trials of probiotics for eczema that examined sensitization to foods as a secondary endpoint [32, 34, 35] . In fact, one trial conducted in the Netherlands showed a trend toward an increase in sensitization rates to foods after 1 and 2 years of treatment with probiotics as compared with placebo [35] . Given these data, probiotics do not appear to be reliable methods for prevention or treatment of food allergy at this time [44] .
Food antigen-expressing, engineered probiotic bacteria
Although lactic acid bacteria (e.g. Lactobacillus and Lactococcus spp) have been used in some of the probiotic trials above, these microorganisms are also effective vehicles for antigen delivery via genetic engineering, and have been used in a wide array of immunologic and anti-infective strategies [45] . For use in the field of food allergy, these bacteria can be engineered to express various dietary antigens, and in theory, when administered to mucosal sites, these genetically engineered probiotic bacteria would then deliver the antigen to the mucosa in a Th1-promoting environment.
Although no human studies have been reported to date, there have been reports in murine models studying the administration of Lacotcoccus lactis engineered to express b-lactogolublin (b-lac) (milk) and ovalbumin (egg) [46] [47] [48] . Although methods varied in these studies, each reported evidence to suggest that delivery of an adequate amount of antigen to mucosal sites via expression in engineered Lacotcoccus lactis could either treat or prevent sensitization to a target antigen via a shift in the immune response to a Th1 response or via CD4 þ CD25 þ regulatory T cells expressing TGF-b.
Cytokine-expressing, engineered probiotic bacteria
Instead of engineering Lacotcoccus lactis to express an antigen, some researchers have engineered the bacteria to express regulatory or Th1 cytokines in order to promote tolerance upon administration [49] [50] [51] [52] . For example, in one model, Lacotcoccus lactis transfected to secrete IL-10, administered via intragastric gavage prior to sensitization with b-lac, significantly diminished anaphylactic scores and decreased serum-specific IgE levels after challenge with b-lac [50] . There is also some evidence to suggest that treatment with two different strains of Lacotcoccus lactis, one expressing a Th1 cytokine (IL-12 in this case) and the other expressing an antigen of interest, could lead to a synergistic effect not obtained by administering either alone [49] . Although these methods using engineered Lacotcoccus lactis to achieve tolerance provide an intriguing model with promising data, they have yet to be studied in humans and are far from clinical use.
HELMINTH THERAPY
Treatment of inflammatory and allergic conditions with helminth therapy has been a novel approach that has recently garnered public attention. Many reports have shown a negative association of chronic helminth infection and allergic disease, thus forming one of the bases of the hygiene hypothesis [53] . Unfortunately, strong clinical data from rigorous trials on the use of helminth therapy for allergic diseases are sparse, and perhaps the best trial to date, using Trichuris suis ova for allergic rhinitis, did not show any clinical benefit [54] . Many proponents of helminth therapy still have hope that this therapy may be beneficial, and that immunomodulatory products of the worms, rather than simple infection, may provide the benefit [55] . In addition, given one report of the utility of helminth therapy in a murine model of food allergy and its use in inflammatory bowel disease (another immunologic deviation of the gut) [56, 57] , there is currently an ongoing trial examining the use of T. suis ova in peanut and tree nut allergy (Clinicaltrials.gov identifier: NCT01070498). 
CONCLUSION
Although allergen-specific immunotherapy appears to hold a bright future in the treatment of food allergy, this treatment is not without risks and may not be efficient for those with multiple food allergies. Therefore, effective allergen nonspecific therapies would be an ideal alternative for these individuals as a primary or adjunctive treatment. Various forms of these allergen nonspecific therapies are currently under investigation, and 
